The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...
After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...
So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, ...
Kymera drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial
Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Interestingly, despite the autumn’s upward trend, November’s haul is the first in 2025 that doesn’t outweigh the ...
Canaccord raised the firm’s price target on Regeneron (REGN) to $1,057 from $850 and keeps a Buy rating on the shares. The firm said they expect ...
Morgan Stanley flagged upside risks if pipeline data impresses, Dupixent intellectual property proves more durable, or Eylea HD adoption accelerates. Downside risks include trial setbacks, competitive ...
Regeneron Pharmaceuticals, Inc. REGN announced a collaboration agreement with private company Tessera Therapeutics, Inc. for ...
Following FDA rejections, Regeneron and Scholar Rock are turning to other facilities to clear regulatory logjams created by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback